Ravdin J I, Skilogiannis J
Department of Medicine, University of Virginia School of Medicine, Charlottesville 22908.
Antimicrob Agents Chemother. 1989 Jun;33(6):960-2. doi: 10.1128/AAC.33.6.960.
Current therapy of Entamoeba histolytica infection requires use of multiple agents effective at different body sites, including the intestinal lumen, intestinal tissue, and liver. Azithromycin and CP-63,956, new extended-half-life macrolides which reach high levels in tissue, exhibit in vitro antiamebic activity at 18 or 48 h of incubation at concentrations comparable to that of erythromycin and slightly higher than that of metronidazole. Azithromycin and CP-63,956 have the potential to be useful therapeutic agents for all types of E. histolytica infection.
目前对溶组织内阿米巴感染的治疗需要使用多种对不同身体部位有效的药物，包括肠腔、肠组织和肝脏。阿奇霉素和CP-63,956是新型的半衰期延长的大环内酯类药物，在组织中可达到较高水平，在体外培养18或48小时时，其抗阿米巴活性的浓度与红霉素相当，略高于甲硝唑。阿奇霉素和CP-63,956有可能成为治疗所有类型溶组织内阿米巴感染的有效治疗药物。
